Perimenopause isn’t vague. It’s measurable, quantifiable, and backed by data that most women never see. Here are the numbers — and the peptides that map to each one.
| Symptom | Prevalence | Primary Peptide | Evidence Level |
|---|---|---|---|
| Hot flashes / night sweats | 75% | Kisspeptin-10 | Phase II trials |
| Sleep disruption | 61% | DSIP + CJC-1295/Ipa | Preclinical + clinical obs. |
| Mood changes / anxiety | 55% | Selank | Russian clinical studies |
| Weight gain | 52% | Semaglutide / Tirzepatide | FDA-approved |
| Brain fog | 47% | NAD+ + Selank | Mechanistic + clinical obs. |
| Joint pain | 45% | BPC-157 + TB-500 | Preclinical (extensive) |
| Hair thinning | 40% | GHK-Cu | Human clinical (topical) |
| Low libido | 38% | PT-141 (Vyleesi) | FDA-approved (HSDD) |
| Skin aging | — | GHK-Cu + Glutathione | Human clinical (topical) |
= FDA-approved = Clinical/preclinical evidence = Anecdotal only
Nearly all women experience some symptoms, but severity varies. 75% experience hot flashes (NAMS data), 61% report sleep disruption, and over 50% experience mood changes and weight gain. Many women experience multiple symptoms simultaneously, which is why single-symptom treatments often feel inadequate.
The average onset is around age 47, but it can begin as early as the late 30s or as late as the mid-50s. The transition lasts 4-10 years before menopause (defined as 12 months after your last period). Family history, smoking, and certain medical conditions can affect timing.
Lost productivity from symptoms including brain fog, fatigue, sleep disruption, and mood changes. Many women reduce work hours, take sick days, or leave the workforce entirely during peak symptom years. The Flo Health 2025 estimate accounts for both direct costs (healthcare spending) and indirect costs (productivity loss, career impact).
Two peptide-based treatments overlap with perimenopause symptoms: semaglutide/tirzepatide for weight management and PT-141 (Vyleesi) for low libido (HSDD in premenopausal women). For hot flashes specifically, the FDA has approved fezolinetant and elinzanetant (non-hormonal, non-peptide). HRT remains the gold standard for vasomotor symptoms. No peptide is FDA-approved specifically for perimenopause as a syndrome.